Analyst Ratings for SAB Biotherapeutics
Portfolio Pulse from Benzinga Insights
SAB Biotherapeutics (NASDAQ:SABS) has received four bullish analyst ratings in the last quarter, with an average price target of $3.25, indicating a potential upside from the current price of $0.755. This average price target has decreased by 18.75% from the previous average of $4.00.
August 21, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SAB Biotherapeutics has received positive analyst ratings, indicating potential upside.
The bullish analyst ratings for SAB Biotherapeutics indicate a positive outlook for the stock. The average price target of $3.25 suggests a potential upside from the current price of $0.755. However, the decrease in the average price target from $4.00 to $3.25 may suggest some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100